NovaScan Announces the Launch of a Human GI trial for its nsCanary™ Cancer Detection Device
January 10th, 2023 by NovaScan 

Jan 9, 2023, Chicago, IL – NovaScan, a clinical stage oncology company based in Chicago, announced that it has started a human GI clinical...

NovaScan’s Les Bogdanowicz Invited to Present Results at CHEST Annual Meeting
August 17th, 2022 by NovaScan 

NovaScan, an emerging oncology company based in Chicago, announced that CTO Les Bogdanowicz, PhD has been invited to present the results fro...

NovaScan Invited for Poster Presentation at ACG Annual Meeting
August 17th, 2022 by NovaScan 

NovaScan, a clinical stage oncology company based in Chicago, announced that it will be presenting a poster at ACG Annual Scientific Meeting...

Dr Amit Mehta to Advise NovaScan
August 10th, 2022 by NovaScan 

Dr Amit Mehta to Advise NovaScan on Ex Vivo Scanning Product

...
NovaScan announces Luminary Scientific Advisory Board Leaders in Pulmonary and Gastroenterology
May 5th, 2022 by NovaScan 

Chicago IL: NovaScan, a clinical-stage oncology company based in Chicago, has announced the appointment of luminaries in interventional pulm...

NovaScan Lung Studies Published in a Leading Peer Reviewed Journal
March 1st, 2022 by NovaScan 

NovaScan, a clinical-stage oncology company based in Chicago and Milwaukee, recently had its publication titled "The Cole Relaxation Freque...

NovaScan Completes $8MM Series B Financing
November 18th, 2021 by NovaScan 

CHICAGO, IL, USA, November 17, 2021 /EINPresswire.com/ -- NovaScan, a clinical stage oncology company pioneering a new low cost point of c...

NovaScan Fully Subscribes and Completes $3MM Financing
January 22nd, 2021 by NovaScan 

NovaScan, an emerging oncology company based in Chicago and Milwaukee, has announced that it has completed a $3MM financing.

...